A patient with pulmonary metastasis from breast cancer after surgery who responded to S-1

• Published in: Gan to kagaku ryoho Vol. 34; no. 7; p. 1143
• Main Authors: Yoneyama, Kimiyasu, Yamada, Aki, Koshida, Yoshitomo, Toriumi, Fumiki, Murayama, Takaya, Toeda, Hiroyuki, Imazu, Yoshihiro, Motegi, Katsuhiko, Akamatsu, Hidetoshi, Ooyama, Renpei
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.07.2007
• Subjects: Adenocarcinoma - secondary; Adenocarcinoma - surgery; Antigens, Tumor-Associated, Carbohydrate - blood; Antimetabolites, Antineoplastic - therapeutic use; Biomarkers, Tumor - blood; Bone Neoplasms - radiotherapy; Bone Neoplasms - secondary; Breast Neoplasms - pathology; Breast Neoplasms - surgery; Carcinoembryonic Antigen - blood; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Lung Neoplasms - drug therapy; Lung Neoplasms - secondary; Lymph Nodes - pathology; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Mucin-1 - blood; Oxonic Acid - therapeutic use; Quality of Life; Tegafur - therapeutic use
• ISSN: 0385-0684

We report a 60-year-old female with pulmonary metastasis from breast cancer who responded to S-1. In November 2001, she underwent surgery. In October 2005, relapse was detected. As there was no hormone sensitivity, chemotherapy was selected, and oral administration of S-1 at 120 mg/day (2 divided doses) was initiated. After the fourth course, the tumor marker level returned to the reference value. Thoracic CT at the end of the sixth course revealed the disappearance of the metastatic focus. Adverse reactions during the administration period were mild. S-1 showed potent antitumor effects and good tolerance, and it may be useful for treating metastatic/recurrent breast cancer.